Year: 2021
Type: article
Abstract: Introduction: Immunotherapy is being used for the past five years either as first line or second line treatment with great results.Chemotherapy and radiotherapy have been also used as combination to immunotherapy to further enhance this type of treatment.Intratumoral treatment has been previously proposed as a treatment option for certain non-small cell lung cancer patients.Patients and Methods: We recruited in total seventy four patients with non-small cell lung cancer in their second line treatment who received only chemotherapy in their first line treatment with programmed death-ligand-1 ≤ 50.Only adenocarcinoma or squamous cell carcinoma, and all negative for epidermal growth factor receptor, anaplastic lymphoma kinase, proto-oncogene tyrosine-protein kinase-1 and proto-oncogene B-Raf.Data were first examined with descriptive statistics choosing frequencies for categorical variables and histograms for the continuous ones.Twenty five received only intravenous immunotherapy and forty-nine intravenous cisplatin with immunotherapy.Data were first examined with descriptive statistics choosing frequencies for categorical variables and histograms for the continuous ones. Results:The relationships between changes of performance status and disease progression were examined via a single correspondence analysis.The two-dimensional scores (coordinates) derived from the correspondence analysis were then regressed against the predictors to form distinct splits and nodes obtaining quantitative results.The best fit is usually achieved by lowering exhaustively the AICc criterion and looking in parallel the change of R 2 expecting improvements more than 5%.both types of therapy are capable of producing best ameliorative effects, when either the programmed death-ligand-1 expression or parenchymal site in joint with low pack years are present in the sampling data.Conclusions: Intratumoral treatment combination with cisplatin plus immunotherapy indifferent of nivolumab or pembrolizumab combination is an effective choice.In specific for those with endobronchial lesions.Moreover; patients with programmed death-ligand-1 ≥ 50 had their performance status and disease progression improved over the eight month observation.
Source: Journal of Cancer
DOI: 10.7150/jca.55322
Authors: Paul Zarogoulidis, Wolfgang Hohenforst-Schmidt, Haidong Huang, Jun Zhou, Qin Wang, Xiangqi Wang, Ying Xia, Yinfeng Ding, Chong Bai, Christoforos Kosmidis, Konstantinos Sapalidis, Chrysanthi Sardeli, Kosmas Tsakiridis, Bojan Zaric, Tomi Kovacevic, Vladimir Stojsic, Tatjana Sarcev, Daliborka Bursac, Biljana Kukic, Sofia Baka, Evagelia Athanasiou, Dimitrios Hatzibougias, Electra Michalopoulou-Manoloutsiou, Savvas Petanidis, Dimitris Drougas, Konstantinos Drevelegas, Dimitris Paliouras, Nikolaos Barbetakis, Anastasios Vagionas, Lutz Freitag, Aimilios Lallas, Ioannis Boukovinas, Dimitris Petridis, Aris Ioannidis, Dimitris Matthaios, Konstantinos Romanidis, Chrisanthi Karapantzou
Institutions: Second Military Medical University, Aristotle University of Thessaloniki, AHEPA University Hospital, Changhai Hospital, Nanjing Medical University, Interbalkan Medical Center, University of Novi Sad, Institute for Pulmonary Diseases of Vojvodina, Sechenov University, Euromedica, Theageneio General Hospital, University Hospital Zurich, International Hellenic University, GENESIS Hospital, General Hospital of Rhodes, Democritus University of Thrace, University Hospital of Alexandroupolis, Ludwig-Maximilians-Universität München
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $1,337
OpenAlex ID: W3136918147